0000899243-23-011780.txt : 20230426
0000899243-23-011780.hdr.sgml : 20230426
20230426193045
ACCESSION NUMBER: 0000899243-23-011780
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220106
FILED AS OF DATE: 20230426
DATE AS OF CHANGE: 20230426
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRATES JAMES M
CENTRAL INDEX KEY: 0001235598
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41199
FILM NUMBER: 23851335
MAIL ADDRESS:
STREET 1: 88 SIDNEY ST
CITY: CAMBRIDGE
STATE: MA
ZIP: 021394136
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464600503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-683-0917
MAIL ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
3/A
1
doc3a.xml
FORM 3/A SUBMISSION
X0206
3/A
2022-01-06
2022-01-06
0
0001658551
Amylyx Pharmaceuticals, Inc.
AMLX
0001235598
FRATES JAMES M
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET
CAMBRIDGE
MA
02141
0
1
0
0
Chief Financial Officer
Series C-1 Preferred Stock
Common Stock
19482
I
By Trust
This amendment on Form 3/A to the Form 3 originally filed on January 6, 2022 (the "Original Form 3") is being filed solely to include 19,482 shares of Series C-1 Preferred Stock held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee, which were inadvertently omitted from the Original Form 3. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Each share of Series C-1 Preferred Stock is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Series C-1 Preferred Stock has no expiration date.
/s/ Joshua B. Cohen, as Attorney-in-Fact for James Frates
2023-04-26